Immune cell study may unlock kidney protection in type 1 diabetes

NCT ID NCT06694558

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study looks at how blood sugar levels affect immune cells (monocytes) and kidney cells in people with type 1 diabetes and early chronic kidney disease. Researchers will compare participants with better versus worse blood sugar control to see if certain immune cells become more active and damage the kidneys. They will also test whether a diabetes drug called GLP-1 agonist can calm these immune cells in a lab dish. The goal is to better understand the link between blood sugar swings and kidney injury.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this study could help explain why some people with type 1 diabetes develop kidney disease and point toward new ways to protect the kidneys.
What could go wrong
This is an observational study that looks at cells in a lab, not a treatment trial. It may not lead to any direct medical changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE (CKD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.